Business UpdateJun 29, 2026, 09:14 AM
Emergent BioSolutions Secures $52.7M Contract for ACAM2000®
AI Summary
Emergent BioSolutions announced a $52.7 million contract modification from the U.S. Department of Health and Human Services' ASPR. The contract is for the supply of ACAM2000® (Smallpox and Mpox Vaccine) and related items to support national preparedness. Deliveries are anticipated to begin this month. This award reinforces Emergent's role in biodefense and follows recent international approvals for ACAM2000® in Saudi Arabia and Singapore.
Key Highlights
- Emergent BioSolutions awarded $52.7 million contract modification from ASPR.
- Contract is for supplying ACAM2000® (Smallpox and Mpox Vaccine) and ancillaries.
- Deliveries of the vaccine are expected to commence in June 2026.
- The award supports U.S. government's biodefense preparedness against smallpox and mpox.
- This is a modification to Emergent's existing 10-year contract with ASPR.
- Follows recent ACAM2000® approvals in Saudi Arabia and Singapore for mpox prevention.
Price Impact
More from EBS